INSPIRED Symposium Part 3: Prevention and Management of Pediatric Chimeric Antigen Receptor T Cell-Associated Emergent Toxicities
Kevin O. McNerney(Children's Hospital of Philadelphia), Jenna Rossoff(Lurie Children's Hospital), Rebecca Epperly(St. Jude Children's Research Hospital), Nirali N. Shah(National Institutes of Health), Joshua A. Hill(Seattle Pacific University), Pamela L. Wolters(National Cancer Center), Haneen Shalabi(Center for Cancer Research), Rebecca Gardner(Seattle Children's Hospital), Emily M. Hsieh(Children's Hospital of Los Angeles), Aimee C. Talleur(St. Jude Children's Research Hospital)
Cited by 20
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
|Journal of Clinical Oncology|2020|422
CD19 CAR T cell product and disease attributes predict leukemia remission durability
|Journal of Clinical Investigation|2019|355